neuropsychiatric disease

Luminex said its technology will enhance the processing speed and capacity of Assurex's tests.

NEW YORK (GenomeWeb) – Assurex Health today said that the US Department of Veterans Affairs has approved the firm's GeneSight Psychotropic test for use in VA facilities nationwide.

NEW YORK (GenomeWeb News) – Emory University said on Tuesday that it will lead an effort to sequence the genomes of 1,000 people who suffer from 22q11.2 deletion syndrome as part of an international consortium that has received $12 million from the National Institute of Mental Health to study how

NEW YORK (GenomeWeb News) – The National Institute of Mental Health will award around $3 million to fund as many as six projects that pursue research into a genetic microdeletion that has been associated with a range of neuropsychiatric disorders.

NEW YORK (GenomeWeb News) – Pharmacogenomics firm AssureRx Health announced on Wednesday it has closed its Series C financing, raising $12.5 million.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – A public-private consortium to generate and analyze large-scale genomic data from patients with neuropsychiatric diseases has launched.

The Welsh government has awarded over $9 million for a new mental health research center, cancer genetics studies, and a new imaging unit.

The firm's GeneSightRx technology uses DNA from a cheek swab to measure and analyze genetic variants to determine how a patient will respond to psychotropic medications.

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.